Articles

In a study reported in The Lancet Oncology, Garcia-Pelaez and colleagues found that presence of germline truncating pathogenic variants or likely pathogenic variants of CDH1 were associated with hereditary diffuse gastric cancer (HDGC) tumor risk syndrome–related cancer phenotypes (lobular breast cancer, diffuse gastric cancer, and gastric cancer), with no apparent association of these phenotypes with CDH1 missense variants of unknown…

Stomach (gastric) cancer is not very prevalent in the United States, with only 1.5% of all new cancer diagnoses representing the disease. Despite this, data shows minorities — especially Asian Americans — are more vulnerable to stomach cancer. A new study from Stanford headed by Joo Ha Hwang, MD, Ph.D., professor of gastroenterology and hepatology at Stanford…

AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been approved in the European Union (EU) as monotherapy for the treatment of adult patients with advanced HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen. Enhertu is a specifically engineered HER2-directed antibody-drug conjugate (ADC) being jointly developed and commercialised by AstraZeneca and Daiichi…

The United Kingdom’s National Institute for Health and Care Excellence (NICE) has issued final guidance recommending the use of nivolumab (Opdivo) plus chemotherapy as a treatment option for patients with HER2-negative advanced stomach and esophageal cancer.1 Read more>

SINGAPORE – When Associate Professor Too Heng-Phon was about to start biotechnology firm Mirxes back in 2010, he asked several of his PhD students to join him, but also warned them that it would be tough going. Two of them decided to help set up the home-grown biotech firm, which went on to develop test…

Stomach cancer isn’t in the spotlight like other cancers, such as breast and colon cancers. Once the leading cause of cancer deaths in the United States, stomach cancer, also known as gastric cancer, has declined steadily over the past century. Today, stomach cancer accounts for about 1.5% of all new cancers in the U.S. each…

James M. Cleary, MD, Ph.D.: Immunotherapy has made a major impact in the treatment of gastroesophageal cancers. The place where it has probably made the biggest impact for the largest number of patients has been in the treatment of locally advanced esophageal and gastroesophageal junctional cancers. For the longest time, we treated patients with neoadjuvant…

WASHINGTON – Yesterday, the U.S. Senate passed a bipartisan resolution authored by U.S. Senator Todd Young (R-Ind.) marking November 2022 as Stomach Cancer Awareness Month. The resolution was first introduced in 2018 in memory of Indianapolis Star reporter and columnist Matthew Tully, who lost his battle with stomach cancer that year. The resolution was cosponsored…

TOKYO, November 17, 2022 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced positive topline results from the Phase 3 SPOTLIGHT clinical trial evaluating the efficacy and safety of zolbetuximab in combination with mFOLFOX6 (a combination regimen that includes oxaliplatin, leucovorin and fluorouracil). Zolbetuximab is an investigational first-in-class monoclonal…